PLX-2853
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for PLX-2853, covering 2025-04-08 to 2025-04-08. Get the full timeline:
Most recent: Clinical Trial Update: PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) [Phase 1, Phase 2]